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Monotherapy with the anti-CD20 monoclonal antibody rituximab can induce complete
responses (CR) in patients with follicular lymphoma (FL). Resting FcRγIII+ (CD16+)
natural killer (NK) cells respond strongly to rituximab-coated target cells in vitro. Yet,
the contribution of NK cells in the therapeutic effect in vivo remains unknown. Here,
we followed the NK cell repertoire dynamics in the lymph node and systemically during
rituximab monotherapy in patients with FL. At baseline, NK cells in the tumor lymph node
had a naïve phenotype albeit they were more differentiated than NK cells derived from
control tonsils as determined by the frequency of CD56dim NK cells and the expression
of killer cell immunoglobulin-like receptors (KIR), CD57 and CD16. Rituximab therapy
induced a rapid drop in NK cell numbers coinciding with a relative increase in the
frequency of Ki67+ NK cells both in the lymph node and peripheral blood. The Ki67+
NK cells had slightly increased expression of CD16, CD57 and higher levels of granzyme
A and perforin. The in vivo activation of NK cells was paralleled by a temporary loss of
in vitro functionality, primarily manifested as decreased IFNγ production in response to
rituximab-coated targets. However, patients with pre-existing NKG2C+ adaptive NK cell
subsets showed less Ki67 upregulation and were refractory to the loss of functionality.
These data reveal variable imprints of rituximab monotherapy on the NK cell repertoire,
which may depend on pre-existing repertoire diversity.
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INTRODUCTION
Follicular Lymphoma (FL) is the secondmost common non-Hodgkin’s lymphoma and accounts for
20% of all lymphomas. Most patients respond well to series of treatment strategies, but the relapse
rate is high and the disease is in the majority of cases incurable (1). Since the initial demonstration
that monotherapy with rituximab, an antibody recognizing the CD20 antigen expressed on mature
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B cells, could improve the survival in FL (2–4), immunotherapy
has become a corner stone in the therapy of most B cell
lymphomas. One of the major mechanisms of action
for rituximab is antibody-dependent cellular cytotoxicity
(ADCC), which is mediated by natural killer (NK) cells
and/or macrophages (5, 6). NK cells perform ADCC through
engagement of an FcγRIIIA/CD16 receptor to the Fc-part of
antibodies bound to the target cell. This process is known to
trigger strong NK cell activation through different pathways
including release of cytotoxic granules and pro-inflammatory
cytokines as IFNγ (7).
The involvement of NK cells in the clinical effects of rituximab
is indirectly supported by the findings that NK cells are rapidly
cleared from the circulation after therapy with rituximab (8),
and the correlation with polymorphisms in the FcγRIIIA gene
(5, 9, 10). In many clinical studies it is challenging to determine
the isolated immunological response to rituximab because of
different treatment combinations. In one study the outcome in
non-Hodgkin’s lymphoma patients correlated with expansion of
NK cells and increased ADCC after the patients received IL-2 in
addition to rituximab therapy (11). Functional in vitro studies
have shown that rituximab activates a broad range of NK cell
subsets, independently of their expression of self-HLA binding
inhibitory KIRs, thus overriding the need for education (12). On
the other hand, it has been reported that tumor cells can increase
HLA class I expression in response to IFNγ stimulation and
thereby escape NK cell killing. However, the in vivo dynamics of
the NK cell repertoire, both systemically and in the lymph node,
duringmonotherapy with rituximab is largely unexplored. In this
study, we examined the immune repertoire in sequential biopsies
of the affected lymph node and in peripheral blood in FL patients
receiving monotherapy with rituximab. Our results point to a
diversified immunological response where some patients display
a pronounced up-regulation of Ki67 associated with a temporary
drop in NK cell function. The kinetics of the response was linked
to the presence of adaptive NK cell subsets in the patient andmay
hold clues to clinical responsiveness to antibody therapy.
RESULTS
NK Cell Frequency and Phenotype in
Lymph Node and Peripheral Blood
Eight patients diagnosed with follicular lymphoma were included
in the study (Table 1). All patients were previously untreated
and received in total four doses of rituximab (Figure 1A). We
first established multi-color flow cytometry panels to monitor
the immune subset composition in fine needle biopsies from
tumor lymph nodes (LN) and peripheral blood (PB) before
each treatment cycle at a weekly interval. The biopsy sample
collection continued until the tumor lymph nodes were too small
to access. The NK cell frequency in LN samples were consistently
low compared to frequencies seen in PB (Figures 1B,C), with
patients showing both increasing and decreasing trends over
time. However, the relative LN-NK frequency of total CD45+
and CD19− CD20− cells were similar to what we found in tonsil
samples from healthy donors. In agreement with earlier studies
(13), we found a decrease of NK cells in peripheral blood 7 days
after rituximab treatment started manifested as lower frequencies
and lower absolute counts (Figures 1D,E).
Next, we determined the expression of activating and
inhibitory receptors, including killer cell immunoglobulin-like
receptors (KIR), NKG2A and NKG2C, effector molecules and
maturationmarkers on intra-nodal and peripheral bloodNK cells
(Figure 2). In line with previous findings (14, 15), we observed a
dominance of CD56brigh NK cells in tonsils from healthy donors
(average 56%, range 37–71%). Tonsils are widely used as a control
in FL (16, 17), albeit they represent a more inflamed tissue
compared to normal lymph nodes from healthy individuals.
Tonsils contain more differentiated T cells and are more
similar to FL tumors in terms of immune cell composition and
differentiation states (18). Indeed, compared to normal tonsils,
LN-NK cells in FL patients showed an intermediate phenotype,
with an average of 71% CD56dim cells. This intermediate state
was also reflected in the relative expression of CD57, KIRs and
CD16 on CD56dim NK cells when compared to the same subset in
tonsil-derived NK cells and PB-NK cells (Figure 2B). Although
we cannot formally exclude that ILCs contributed to the relative
composition in CD56+CD3- cells in LN and tonsils, ILCS
typically lack CD16, KIR andNKG2A. Furthermore, LN-NK cells
expressed lower levels of the effector molecules Granzyme A/B
and Perforin than PB-NK cells. The maturation and cytotoxic
phenotypes of both LN-NK and PB-NK cells were highly stable
over time with the exception of increased Granzyme B in LN-NK
after treatment and a small increase of NKG2A+ cells in PB-NK
cells 7 days after the first rituximab administration. We can not
formally exclude that dynamics in ILCs contributed to the
Rituximab Therapy Is Associated With a
Rapid Induction of Ki67 Expression
To further dissect the NK cell response to rituximab treatment in
the patients we stained for the intracellular marker Ki67, which is
found in recently divided or cycling cells. Before treatment the
Ki67 level in the patients’ LN-NK cells was higher than tonsil
control NK cells, while PB-NK cells had comparable level to what
was seen in healthy controls (Figures 3A,B). Seven days after
treatment start, we found a consistent increase of Ki67 expression
in both LN-NK and PB-NK. After 14 days the Ki67 expression
had, in most instances, declined to baseline levels and remained
low during the subsequent administration of rituximab. This
indicates the observed induction of Ki67 on NK cells in the
patients was a direct consequence of the rituximab treatment
but that this response was limited to the first administration.
The Ki67+ NK cells at day 7 expressed relatively higher levels
of CD16, CD57, KIRs, NKG2C, Perforin and Granzyme A than
Ki67+ NK cells at baseline, suggesting that NK cell activation was
accompanied with cellular differentiation (Figure 3C).
Temporary Loss of NK Cell Function After
Rituximab Treatment
To assess whether the repertoire dynamics was associated with
changes in NK cell function, we monitored degranulation
(CD107a) and cytokine production (IFNγ) in peripheral blood
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TABLE 1 | Patient characteristics.
ID Age Diagnosis Stage FLIPI Treatment indication Response* Response** Months in
remission+
Subsequent
treatments#
RITFL01 60–65 FL low grade IV Int High tumor burden, B
symptoms
PR CR 5 R-Idelalisib,
R-Bendamustine#
RITFL02 30–35 FL 3A III Low Pain in enlarged lymph
nodes
CR CR 68+
RITFL03 35–40 FL 2 IV High High tumor burden, B
symptoms
PD R-CHOP,
R-Bendamustine,
BEAM+ ASCT#
RITFL04 65–70 FL 2 IV High Progressive disease PR CR 61+
RITFL05 40–45 FL 2 III Int Progressive disease, high
tumor burden
PR PR 17 R#
RITFL06 70–75 FL 2 III High Progressive/bulky disease PR PR 16 R-Bendamustine#
RITFL07 70–75 FL low grade IV High Progressive disease PR CR 57+
RITFL08 80–85 FL low grade III Low Progressive disease PR CR 10 R-Bendamustine#
FLIPI, Follicular Lymphoma International Prognostic Index; PR, partial remission; CR, complete remission; R, rituximab; CHOP, cyclophosphamide, doxorubicine, vincristine and
prednisolon; BEAM, carmustine, etoposide, cytarabine and melphalan; ASCT, autologous stem cell transplantation. *After 10 weeks (1× 4 rituximab); **After 22 weeks (2× 4 rituximab);
+Ongoing remission; #Alive at latest follow up.
FIGURE 1 | Decreased NK cell frequency and cell count in peripheral blood after treatment. (A) Outline of treatment and sample collection in the patients.
(B) Representative flow cytometry staining of CD56+ CD3− NK cells in tumor lymph node and peripheral blood. Frequency CD56+ CD3− NK cells of total tumor
negative and CD45+ cells in (C) lymph node (LN) and (D) peripheral blood (PB). (E) NK cell counts in PB. Patients N = 8, healthy controls N = 10. Differences were
assessed using the Wilcoxon signed rank test for comparisons of matched samples within patients or Mann-Whitney t-test for comparisons between healthy controls
and patients, *p < 0.05.
NK cells after stimulation with 721.221 cells coated with
rituximab (Figure 4A). We found a reduction in multi-
functional responses, primarily due to a significantly decreased
IFNγ-production at day 7 after systemic rituximab treatment
in some but not all patients (Figures 4B,C). NK cell function
gradually returned to normal over the course of 2–3 weeks.
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FIGURE 2 | Tumor lymph node NK cells have an intermediate differentiated phenotype compared to tonsil NK cells and peripheral blood NK cells. (A) Example of flow
cytometry staining of NK cells in tumor lymph node and peripheral blood. (B) Frequency CD56dim NK cells of total CD56+ cells, and frequency NKG2A+, CD57+,
(Continued)
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FIGURE 2 | KIR+, NKG2C+, CD16+, Granzyme A+, Granzyme B+, Perforin+ cells of total CD56dim cells in patient tumor lymph node samples and peripheral
blood, before (light blue) and 7 days (dark blue) after treatment. Tonsil and peripheral blood NK cells from healthy controls are shown in white bars. Patients n = 8,
healthy controls n = 8–10. Differences were assessed using the Wilcoxon signed rank test for comparisons of matched samples within patients or Mann-Whitney
t-test for comparisons between healthy controls and patients, *p < 0.05, **p < 0.01, and ***p < 0.001.
Notably, three of the patients showed an opposite trend with
a more stable or even increased NK cell function at day 7 and
beyond. The relative loss of IFNγ-production appeared to be
most prominent in patients that had a relatively higher induction
of Ki67+ NK cells at day 7 (Figure 4D).
Approximately 30–40% of CMV seropositive donors harbor
expansion of adaptive NK cells expressing high levels of NKG2C
and CD57 (19, 20). This specific NK cell subset displays
epigenetic imprinting of the IFN promoter and responds strongly
to antibody-coated targets (21–23). Although the number of
patients in the study is small, stratifying the patients into two
groups based on presence of NKG2C expansions above 5%
revealed a trend toward amore stable IFNγ-production over time
in patients with adaptive NKG2C+ cells (Figures 4E,F).
Rituximab Pretreatment Reduces
Antibody-Dependent NK Cell Functions
in vitro
To further study the effect of rituximab on NK cell proliferation
and ADCC function PBMCs from healthy donors were cultured
with 1 ng/ml IL-15 to induce proliferation, in the presence
or absence of a short term (48 h) stimulation with rituximab
(10µg/ml). Rituximab pretreatment resulted in a small but
significant increase in the proportion of rapidly cycling NK cells
at day 6 (Figures 5A,B). Under these experimental conditions,
adaptive NKG2C+ NK cells proliferated less than conventional
NK cells (Figure 5C). In agreement with the ex vivo data,
degranulation and cytokine production in response to antibody-
coated target cells were reduced in rapidly proliferating NK
cells (Figure 5D) and in cells with prior exposure to rituximab
(Figure 5E). In line with their low-grade proliferation, NKG2C+
NK cells displayed higher functional responses after rituximab
stimulation (Figure 5F). Hence, at the repertoire level, IFNγ
production was more stable in donors with pre-existing CMV-
driven expansions of NKG2C+ NK cells (Figure 5G).
DISCUSSION
NK cells are believed to contribute to the successful eradication
of malignant B cells following rituximab therapy, but the
mechanism for this is not well-defined. In this study we
performed a detailed analysis of the dynamics including
functional and phenotypical characteristics of the NK cell
response to rituximab treated FL-patients. NK cells in tumor-
affected lymph nodes had an immature phenotype, albeit more
differentiated than tonsil NK cells used as negative control. Both
lymph node and peripheral blood NK cells showed signs of
activation/proliferation during the first week after initiation of
rituximab treatment. These phenotypic imprints were linked to a
temporary loss in functionality. These early dynamic events may
hold clues to the role of NK cell-mediated ADCC in the clinical
response to therapeutic monoclonal antibodies.
There are surprisingly few studies assessing the NK cell
compartment in primary human lymph nodes and tonsils and to
our knowledge there is none describing dynamic events following
immunomodulatory therapy. Healthy human tonsils and lymph
nodes were found to contain 5 and 0.4% NK cells, respectively
(15). It was previously reported that 95% of lymph node NK
cells are CD56bright (14). We confirm these low numbers of
NK cells in lymphoid tissues although NK cell frequencies were
similarly low in tumor lymph node biopsies and healthy control
tonsils. However, the tumor-affected lymph nodes contained
relatively higher numbers of CD56dim NK cells. In addition,
several surface receptors associated with a mature cytotoxic
phenotype, including CD16, CD57, and KIRs, were expressed at
a higher level in tumor-affected lymph nodes compared to tonsil
controls. This could reflect an ongoing immunological response
to the tumor cell growth.
Besides cytotoxic effector functions, activated NK cells can
produce high levels of cytokines, which may in turn lead to
further activation of several immune cell types including T cells
(8). Previous studies have shown that cytotoxic lymphocytes
predominantly reside at the periphery of follicles and in the
interfollicular areas close to T cells (24). In this compartment, the
interplay with T cells secreting IL-2 leads to NK cell-mediated
release of IFNγ (14). IFNγ release can lead to up-regulation of
HLA molecules and thereby affect the T cell response, it also
stimulates macrophages to increased phagocytosis in addition
to lymphocyte recruitment and a prolonged activation (25). An
increased CD8+ T-cell infiltrate correlates to better prognosis in
FL (26) although chronic stimulation of intra-nodal T cells may
also lead to T-cell exhaustion in FL patients (27, 28).
Release of pleiotropic cytokines by LN-NK cells in response to
rituximab can furthermore influence the local immune response
through increased expression of the high-affinity Fcγ receptors
CD64 on granulocytes (29) and through M1-polarization of
macrophages (30). In vitro studies have suggested rituximab to
induce cytotoxic T cell response after promoting phagocytosis
and dendritic cell cross-presentation (31). Indeed, anti-CD20
therapy led to a long-lasting protection against CD20+ tumor
cells in mice by inducing a CD8+ and CD4+ dependent cellular
immune response (32). Similarly, vaccination with autologous
DC following low dose of intra-nodal rituximab was associated
with CR and induction of systemic immunity in patients with
FL (33).
We noted a rapid but temporary decline in NK cell numbers
in the periphery after rituximab therapy. Unfortunately it was not
possible to trace the fate of these cells and determine whether they
egressed from peripheral blood to reach other compartments.We
did not detect any reciprocal increase in NK cell frequencies in
the lymph node. It is possible that we missed the kinetics of these
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FIGURE 3 | Increased frequency of Ki67+ CD56dim NK cells after rituximab treatment. (A) Representative example of flow cytometry staining and (B) summary
showing frequency Ki67+ CD56dim NK cells before (light blue) and after (dark blue) treatment in tumor lymph node and peripheral blood. (C) Expression of NKG2A,
CD57, KIRs, NKG2C, CD16, granzyme A/B and perforin on Ki67 positive and negative CD56dim NK cells from peripheral blood Healthy controls are shown in white.
Patients N = 8, healthy controls N = 10. Differences were assessed using the Wilcoxon signed rank test for comparisons of matched samples within patients or
Mann-Whitney t-test for comparisons between healthy controls and patients, *p < 0.05 and **p < 0.01.
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FIGURE 4 | Altered function of peripheral blood CD56dim NK cells after treatment. (A) Flow cytometry staining of CD107a and IFNγ on peripheral blood NK cells from
patients, with or without tumor cell and rituximab stimulation. (B) Relative frequency of CD107a and IFNγ positive CD56dim NK cells after stimulation with 721.221
cells coated with rituximab, in patients (n = 7) before (Day 0) and after (Day 7) treatment. (C) CD56dim NK cell IFNγ response to 721.221 cells coated with rituximab in
the individual patients before and during the first 3 weeks after therapy (N = 7). (D) Correlation of relative IFNγ response to relative Ki67 expression (day 7 compared
to day 0). (E) Flow cytometry staining showing NKG2C and CD57 expression in the individual patients at Day 0. (F) Relative IFNγ-production at day 7 in patients with
less or more than 5% NKG2C+ CD56dim NK cells.
early events by sampling the lymph node weekly. However, Ki67
expression was induced on both PBL-NK and LN-NK 1 week
after the first dose of rituximab. The NK cell number in lymph
node biopsies was too low to allow further subset analysis of the
emerging Ki67+ NK cell population. In PBL, Ki67+ NK cells
had a slightly more differentiated phenotype at day 7 than day
0 and compared to Ki67+ NK cells in healthy controls. These
data suggest that rituximab triggers a rapid proliferative NK
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FIGURE 5 | In vitro model for altered NK cell functions upon rituximab pre-treatment. (A,B) NK cells from CMV-seropositive healthy donors were cultured for 6 days
with low-dose IL-15 (1 ng/ml) in the presence or absence of rituximab (10µg/ml) for the first 48 h. The percentage of rapidly cycling NK cells (at least 2 divisions) was
analyzed after 6 days of IL-15 culture with (+) or without (–) rituximab pretreatment. (C) The ratio of rapid versus slowly cycling NK cells as defined in panel A, stratified
based on expression of NKG2C. (D) Degranulation (CD107a) and cytokine production (IFNγ) after stimulation with rituximab-coated 721.221 cells in rapidly and slowly
cycling NK cells. (E) Degranulation (CD107a) and cytokine production (IFNγ) after stimulation with rituximab-coated 721.221 cells in bulk NK cells with (+) or without
(–) rituximab pretreatment in vitro. (F) Degranulation (CD107a) and cytokine production (IFNγ) after stimulation with rituximab-coated 721.221 cells in NKG2C+ and
NKG2C- NK cells. (G) Healthy donors were divided into those with (>5%) or without (<5%) a significant expansion of NKG2C+ NK cells. The relative degranulation
(rCD107a) and relative IFNγ production (rIFNγ) in response to ADCC stimulation for cells with or without pretreatment with rituximab. Statistical significance between
paired samples was calculated using a Wilcoxon test and indicated on bars, whereas a Wilcoxon singed-rank test was used to calculate the statistical significance
against a fixed value. Non-paired samples were analyzed by a Mann-Whitney t-test (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001).
cell response associated with cellular differentiation. Intriguingly,
the phenotypic imprints were normalized and had returned
to baseline at day 14 in most patients. Also, the NK cell
repertoires were stable following the 2nd to 4th treatment cycle.
In one of the patients we noted a slower kinetics with a peak
in Ki67 expression occurring at day 14. This slow kinetics
correlated with a delayed clinical response to the treatment in this
particular patient.
In the majority of the patients we observed an attenuated
response to in vitro stimulation with rituximab-coated target cells
1 week after the first treatment cycle. This drop in functionality
coincided in time with the increased expression of Ki67. In
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fact, we noted a positive correlation between the degree of Ki67
upregulation at day 7 and loss of IFNγ production in vitro.
Ki67 may reflect a more general NK cell activation but it is
also possible that these cells have undergone recent cell division.
Onset of cell division and the associated changes in metabolism
may reprogram the functionality of the cell leading to decreased
cytokine production. Therefore, it is tempting to speculate that
the decreased in vitro functionality observed at day 7 represent
a form of functional exhaustion following the primary in vivo
response to systemic rituximab therapy. If this is the case,
variation in the in vitro response may hold clues to the efficacy of
the therapy. Supporting this notion, one in vitro study reported
hyporesponsiveness in NK cells following pre-treatment with
rituximab (34). In this short-term model, exposure to rituximab
primarily affected cytotoxicity while no effect was seen on the
IFNγ production. In contrast, our data showed altered cytokine
production while the degranulation toward rituximab-coated
target cells was less affected. Furthermore, we found stable or
increased levels of the cytotoxic effector molecules granzyme
A/B and perforin after treatment, suggesting the ability to
perform cellular cytotoxicity remained intact. In a few patients
we observed an opposite trend with a stable or even increased
functional response at day 7. Intriguingly, these patients had
evidence of a weaker systemic imprint of rituximab therapy and
harbored significant adaptive NK cell populations determined by
the expression of NKG2C and CD57. Adaptive NK cells have
increased capacity to produce IFNγ in response to antibody-
coated target cells due to epigenetic changes in the IFNγ
promoter (21–23, 35). Patients having NKG2C+ NK cells could
theoretically thus already from the start be better equipped for
cytokine production in response to rituximab treatment thereby
explaining their functional stability over time. Although these
data are based on few patients, this notion was supported by
an in vitro model for rituximab-induced proliferation where
we noted a profound loss of function in proliferating NK
cells that was less dramatic in donors harboring adaptive NK
cell expansions, linked to the poor proliferative response and
maintained function in NKG2C+ NK cells.
The primary objective of our study was to explore longitudinal
phenotypic and functional imprints of rituximab monotherapy.
The study was underpowered to link immune variation to clinical
outcomes. Nevertheless, the diversified response observed in this
study suggest that probing dynamic systemic and local immune
imprints may hold utility as a metrics of the patients’ ability to
respond to therapy and thereby a predictor treatment efficacy.
MATERIALS AND METHODS
Patients
This study was approved by the Regional Ethical Review Board
in Stockholm, Sweden. Fine needle biopsies from tumor lymph
nodes and peripheral blood were collected after informed consent
from 8 patients diagnosed with follicular lymphoma. Samples
were obtained before treatment, and 7, 14, and 21 days after the
treatment with rituximab started. Collection of the fine needle
biopsies ended earlier if the tumor lymph nodes were too small
to access. Age matched healthy control cells were collected from
buffy coats and tonsils. The cells from peripheral blood and
tonsils were enriched by density gradient (Ficoll-Hypaque; GE
Healthcare) and PBMC’s, cells from tonsils and fine needle biopsy
cells were cryopreserved in 90% FCS and 10% DMSO for later
analysis. CMV serology was determined using an ELISA-based
assay on plasma obtained during sample preparation. Purified
nuclear antigen (AD 169) was used and the cut-off level for
seropositivity was an absorbance of >0.2 dilution of 1/100.
Antibodies and Flow Cytometry
The following conjugated monoclonal antibodies (mAbs) were
used: Ki67 (clone: B56), CD14 (MφP9), CD57 (NK-1), Granzyme
B (GB11), CD107a (H4A3), IFNγ (B27), CD19 (HIB19)
from BD Biosciences, NKG2A (z199), CD3 (UHCT1), CD56
(N901), KIR2DL2/3/S2 (GL183), KIR2DL1/S1 (EB6), CD19
(J3-119) from Beckman Coulter, CD16 (3G8), CD20 (2H7),
CD45 (HI30), Granzyme A (CB9), KIR3DL1 (dx9) from
BioLegend, Perforin (dG9), κ-chain (TB28-2), λ-chain (TB28-
2), Granzyme K (G3H69) from eBiosciences, KIR2D-biotin
(NKVFS1), KIR3DL1/2-biotin (5.133), KIR2DL1 (REA284) from
Miltenyi, NKG2C (134591) and 2DL3 (180701) from R&D
Systems. For phenotypic analysis of cells, PBMCs and cells
from fine needle biopsies were incubated at 4◦C in the
dark with surface mAbs, washed with PBS and additionally
stained with Streptavidin-Qdot655 (Invitrogen) and Live/Dead
fixable aqua dead cell stain (Invitrogen). After wash with
PBS the cells were fixed and permeabilized with fix/perm kit
(eBiosciences), washed and stained with intracellular mAbs. Data
were acquired in FACSDiva software on a BD LSRFortessa
equipped with a 488-nm laser, a 633-nm laser, a 405-nm laser,
and a 562-nm laser. Acquired data were analyzed in FlowJo 9.8
(Tree Star).
Functional Flow Cytometry Assay
PBMCs were rested overnight at 37◦C and 5% CO2 in RPMI
1640 supplemented with 10% FCS and 5mM L-glutamine.
Cells were mixed with 721.221 target cells at a 10:1 ratio and
incubated 6 h with or without rituximab (1µg/ml). CD107a
antibody, GolgiStop (1:1,500, BD Biosciences) and GolgiPlug
(1:1,000, BD Biosciences) were added after 1 h of co-incubation.
At the end of the assay additional CD107a antibody was added
together with the surface mAbs, following staining procedure as
described above.
In vitro Experiments
PBMCs were isolated from buffy coats obtained from healthy
blood donors from the Oslo University Hospital Blood bank
(donor informed consent included). Cells were labeled with
CellTraceTM Violet or CFSE TM dye for cell proliferation analysis
according to the kit’s instructions (Molecular Probes). CTV-
/CFSE -labeled PBMCs were culture in RMPI 1640 media
(Sigma) with antibiotics (penicillin/ streptomycin; Sigma) and
10% human, heat-inactivated AB serum (Trina Bioreaktives)
plus 1 ng/ml IL-15 (Miltenyi Biotec) for 6 days at 37◦C
with or without 10 µg/ ml rituximab (Roche) for the first
48 h. On day 2 and 4 the medium was replaced with fresh
medium and IL-15. After 6 days cells were analyzed for
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the number of dividing NK cells by flow cytometry. In
addition, cells were mixed with 721.221 target cells, which
have been labeled with or without rituximab, at a 1:1 ratio
and incubated for 4 h at 37◦C. CD107a antibodies were
added directly, whereas GolgiStop (1:1,500, BD Bioscience) and
GolgiPlug (1:1,000, BD Bioscience) were added after 1 h of co-
incubation. At the end of the culture, cells were stained with
surface and intracellular mAbs, following staining procedure as
describe above.
Statistical Analysis
For comparisons Wilcoxon matched test or for unpaired groups
Mann-Whitney test was used. p-values: ∗ < 0.05, ∗∗ < 0.01, ∗∗∗
< 0.001, ∗∗∗∗ < 0.0001. Analysis was performed using GraphPad
Prism 6 software.
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